Noncovalently associated cell-penetrating peptides for gene delivery applications

Therapeutic Delivery

Volumn 4, Issue 6, 2013, Pages 741-757

  Alhakamy, Nabil A ^a   Nigatu, Adane S ^b   Berkland, Cory J ^a,c   Ramsey, Joshua D ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b Oklahoma State University   (United States)

^c University of Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOPOLYMER; CALCIUM CHLORIDE; CELL PENETRATING PEPTIDE; CHIMERIC PROTEIN; CHOLESTEROL ESTER; CLATHRIN; DISULFIDE; DNA; HERRING PROTAMINE; HISTIDINE; LIPOFECTAMINE; MELITTIN; OLIGOMER; PENETRATIN; POLYARGININE; POLYDISULFIDE AMINE; POLYLYSINE; POLYMER; PROTAMINE; RETROVIRUS VECTOR; RNA; SMALL INTERFERING RNA; SYNTHETIC PEPTIDE; TRANSACTIVATOR PROTEIN; TRANSPORTAN; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

CAVEOLA; CELL MEMBRANE; COMPLEX FORMATION; COVALENT BOND; DRUG CONJUGATION; DRUG FORMULATION; DRUG PENETRATION; ENDOCYTOSIS; GENE DELIVERY SYSTEM; GENE VECTOR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; PINOCYTOSIS; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; STATIC ELECTRICITY;

EID: 84878715268     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.44     Document Type: Review

References (133)

1. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157(2), 195-206 (2009).
2. Hoyer J, Neundorf I. Peptide vectors for the nonviral delivery of nucleic acids. Acc. Chem. Res. 45(7), 1048-1056 (2012).
3. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J. Pharm. Sci. 92(2), 203-217 (2003).
4. Munyendo WLL, Lv H, Benza-Ingoula H, Baraza LD, Zhou J. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules 2(2), 187-202 (2012).
5. Ilina P, Hyvonen Z, Saura M, Sandvig K, Yliperttula M, Ruponen M. Genetic blockage of endocytic pathways reveals differences in the intracellular processing of non-viral gene delivery systems. J. Control. Release 163(3), 385-395 (2012).
6. Medina-Kauwe L, Xie J, Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. Gene Ther. 12(24), 1734-1751 (2005).
7. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8, 343-375 (2006).
8. Mäe M, Myrberg H, El-Andaloussi S, Langel Ü. Design of a tumor homing cell-penetrating peptide for drug delivery. Int. J. Pept. Res. Ther. 15(1), 11-15 (2009).
9. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60(4), 452-472 (2008).
10. Deshayes S, Morris M, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62(16), 1839-1849 (2005).
11. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7(1), 33-40 (2001).
12. De Jong G, Telenius A, Vanderbyl S, Meitz A, Drayer J. Efficient in vitro transfer of a 60-Mb mammalian artificial chromosome into murine and hamster cells using cationic lipids and dendrimers. Chromosome Res. 9(6), 475-485 (2001).
13. Kreiss P, Mailhe P, Scherman D et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res. 27(19), 3792-3798 (1999).
14. Said Hassane F, Saleh A, Abes R, Gait M, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67(5), 715-726 (2010).
15. Lundberg M, Wikström S, Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8(1), 143-150 (2003).
16. Nakase I, Niwa M, Takeuchi T et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10(6), 1011-1022 (2004).
17. Foerg C, Ziegler U, Fernandez-Carneado J et al. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. Biochemistry 44(1), 72-81 (2005).
18. Järver P, Langel U. Cell-penetrating peptides - a brief introduction. Biochim. Biophys. Acta 1758(3), 260-263 (2006).
19. Lorents A, Kodavali PK, Oskolkov N, Langel Ü, Hällbrink M, Pooga M. Cell-penetrating peptides split into two groups based on modulation of intracellular calcium concentration. J. Biol. Chem. 287(20), 16880-16889 (2012).
20. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280(15), 15300-15306 (2005).
21. Fittipaldi A, Ferrari A, Zoppé M et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278(36), 34141-34149 (2003).
22. Guterstam P, Madani F, Hirose H et al. Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim. Biophys. Acta 1788(12), 2509-2517 (2009).
23. Jiao C-Y, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 284(49), 33957-33965 (2009).
24. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim. Biophys. Acta 1816(2), 232-246 (2011).
25. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cell. Biochemistry 43(9), 2438-2444 (2004).
26. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24(11), 1977-1992 (2007).
27. Nakase I, Akita H, Kogure K et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc. Chem. Res. 45(7), 1132-1139 (2012).
28. Silhol M, Tyagi M, Giacca M, Lebleu B, Vives E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 269(2), 494-501 (2002).
29. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18(7), 385-393 (2012).
30. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55(6), 1189-1193 (1988).
31. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl Acad. Sci. USA 88(5), 1864-1868 (1991).
32. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271(30), 18188-18193 (1996).
33. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272(25), 16010-16017 (1997).
34. Lindgren M, Langel Ü. Classes and prediction of cell-penetrating peptides. In: Cell- Penetrating Peptides Methods and Protocols. Langel Ü (Ed.). Springer, NY, USA 683, 3-19 (2011).
35. Wang H, Zhong CY, Wu JF, Huang YB, Liu CB. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J. Control. Release 143(1), 64-70 (2010).
36. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today (15-16), 850-860 (2012).
37. Fawell S, Seery J, Daikh Y et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl Acad. Sci. USA 91(2), 664-668 (1994).
38. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269(14), 10444-10450 (1994).
39. Pooga M, Soomets U, Hällbrink M et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16(9), 857-861 (1998).
40. Wender PA, Rothbard JB, Jessop TC, Kreider EL, Wylie BL. Oligocarbamate molecular transporters: design, synthesis, and biological evaluation of a new class of transporters for drug delivery. J. Am. Chem. Soc. 124(45), 13382-13383 (2002).
41. Pujals S, Fernández-Carneado J, López- Iglesias C, Kogan MJ, Giralt E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta 1758(3), 264-279 (2006).
42. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10(7), 290-295 (2000).
43. Gratton JP, Yu J, Griffith JW et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9(3), 357-362 (2003).
44. Mo RH, Zaro JL, Shen WC. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol. Pharm. 9(2), 299-309 (2011).
45. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558(1), 63-68 (2004).
46. Liu BR, Lin MD, Chiang HJ, Lee HJ. Arginine-rich cell-penetrating peptides deliver gene into living human cells. Gene 505(1), 37-45 (2012).
47. Won YW, Kim HA, Lee M, Kim YH. Reducible poly (oligo-d-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol. Ther. 18(4), 734-742 (2009).
48. Åmand HL, Nordén B, Fant K. Functionalization with C-terminal cysteine enhances transfection efficiency of cell-penetrating peptides through dimer formation. Biochem. Biophys. Res. Commun. 418(3), 469-474 (2012).
49. Astriab-Fisher A, Sergueev DS, Fisher M, Ramsay Shaw B, Juliano RL. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60(1), 83-90 (2000).
50. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25(14), 2730-2736 (1997).
51. Morris MC, Chaloin L, Méry J, Heitz F, Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res. 27(17), 3510-3517 (1999).
52. Morris MC, Depollier J, Méry J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19(12), 1173-1176 (2001).
53. Tung C-H, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg. Med. Chem. 10(11), 3609-3614 (2002).
54. Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39-43 (2007).
55. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today 9(23), 1012-1019 (2004).
56. Nakase I, Hirose H, Tanaka G et al. Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis. Mol. Ther. 17(11), 1868-1876 (2009).
57. Andreu D, Merrifield R, Steiner H, Boman HG. N-terminal analogs of cecropin A: synthesis, antibacterial activity, and conformational properties. Biochemistry 24(7), 1683-1688 (1985).
58. Lindgren M, Rosenthal-Aizman K, Saar K et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 71(4), 416-425 (2006).
59. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57(4), 579-596 (2005).
60. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59(2), 134-140 (2007).
61. Männistö M, Vanderkerken S, Toncheva V et al. Structure-activity relationships of poly (l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J. Control. Release 83(1), 169-182 (2002).
62. McKenzie DL, Collard WT, Rice KG. Comparative gene transfer efficiency of low molecular weight polylysine DNA-condensing peptides. J. Pept. Res. 54(4), 311-318 (1999).
63. Gottschalk S, Sparrow J, Hauer J et al. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther. 3(5), 448 (1996).
64. Wadhwa MS, Collard WT, Adami RC, McKenzie DL, Rice KG. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconj. Chem. 8(1), 81-88 (1997).
65. Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG. Stability of peptide-condensed plasmid DNA formulations. J. Pharm. Sci. 87(6), 678-683 (1998).
66. Rydberg HA, Matson M, Åmand HL, Esbjorner EK, Nordén B. Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides. Biochemistry 51(27), 5531-5539 (2012).
67. Walrant A, Correia I, Jiao CY et al. Different membrane behaviour and cellular uptake of three basic arginine-rich peptides. Biochim. Biophys. Acta 1808(1), 382-393 (2011).
68. Plank C, Tang MX, Wolfe AR, Szoka FC. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum. Gene Ther. 10(2), 319-332 (1999).
69. Åmand HL, Boström CL, Lincoln P, Nordén B, Esbjörner EK. Binding of cell-penetrating penetratin peptides to plasma membrane vesicles correlates directly with cellular uptake. Biochim. Biophys. Acta 1808(7), 1860-1867 (2011).
70. Åmand HL, Fant K, Nordén B, Esbjörner EK. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem. Biophys. Res. Commun. 371(4), 621-625 (2008).
71. Mitchell D, Steinman L, Kim D, Fathman C, Rothbard J. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56(5), 318-325 (2000).
72. Kim HH, Choi HS, Yang JM, Shin S. Characterization of gene delivery in vitro and in vivo by the arginine peptide system. Int. J. Pharm. 335(1-2), 70-78 (2007).
73. Lundberg M, Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem. Biophys. Res. Commun. 291(2), 367-371 (2002).
74. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev. 60(4), 530-536 (2008).
75. Kim WJ, Christensen LV, Jo S et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Molecular Ther. 14(3), 343-350 (2006).
76. Koo H, Kang H, Lee Y. Analysis of the relationship between the molecular weight and transfection efficiency/cytotoxicity of Poly-l-arginine on a mammalian cell line. Bull. Korean Chem. Soc. 30(4), 927 (2009).
77. Futaki S, Ohashi W, Suzuki T et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconj. Chem. 12(6), 1005-1011 (2001).
78. Baoum A, Ovcharenko D, Berkland C. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. Int. J. Pharm. 427(1), 134-142 (2012).
79. Midoux P, LeCam E, Coulaud D, Delain E, Pichon C. Histidine containing peptides and polypeptides as nucleic acid vectors. Somat. Cell Mol. Genet. 27(1-6), 27-47 (2002).
80. Midoux P, Kichler A, Boutin V, Maurizot J-C, Monsigny M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconj. Chem. 9(2), 260-267 (1998).
81. Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML. Inf luenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl Acad. Sci. USA 89(17), 7934-7938 (1992).
82. Midoux P, Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconj. Chem. 10(3), 406-411 (1999).
83. Lundberg P, El-Andaloussi S, Sütlü T, Johansson H, Langel Ü. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21(11), 2664-2671 (2007).
84. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 9(1), 18-29 (2007).
85. Chen CP, Kim J, Steenblock E, Liu D, Rice KG. Gene transfer with poly-melittin peptides. Bioconj. Chem. 17(4), 1057-1062 (2006).
86. Wyman TB, Nicol F, Zelphati O, Scaria P, Plank C, Szoka FC. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36(10), 3008-3017 (1997).
87. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl Acad. Sci. USA 96(1), 91-96 (1999).
88. Escriou V, Carrière M, Scherman D, Wils P. NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv. Drug Deliv. Rev. 55(2), 295-306 (2003).
89. Lanford RE, Butel JS. Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen. Cell 37(3), 801 (1984).
90. Collas P, Husebye H, Aleström P. The nuclear localization sequence of the SV40 T antigen promotes transgene uptake and expression in zebrafish embryo nuclei. Transgenic Res. 5(6), 451-458 (1996).
91. Subramanian A, Ranganathan P, Diamond SL. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat. Biotechnol. 17(9), 873-877 (1999).
92. Nitin N, LaConte L, Rhee WJ, Bao G. Tat peptide is capable of importing large nanoparticles across nuclear membrane in digitonin permeabilized cells. Ann. Biomed. Eng. 37(10), 2018-2027 (2009).
93. Schätzlein AG. Targeting of synthetic gene delivery systems. J. Biomed. Biotechnol. 2003(2), 149-158 (2003).
94. Hart S. Integrin-mediated vectors for gene transfer and therapy. Curr. Opin. Mol. Ther. 1(2), 197 (1999).
95. White SJ, Nicklin SA, Sawamura T, Baker AH. Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension 37(2), 449-455 (2001).
96. Khondee S, Baoum A, Siahaan TJ, Berkland C. Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells. Mol. Pharm. 8(3), 788-798 (2011).
97. Ginn, SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J. Gene Med. 15(2), 65-77 (2013).
98. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003)
99. Robbins PD, Tahara H, Ghivizzani SC. Viral vectors for gene therapy. Trends Biotechnol. 16(1), 35-40 (1998).
100. Warnes A, Fooks AR. Live viral vectors : construction of a replication-deficient recombinant adenovirus. Methods Mol. Med. 4, 33-45 (1996).
101. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304), 1320-1323 (1997).
102. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60(2), 249-271 (2000).
103. Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum. Gene Ther. 15(11), 1034-1044 (2004).
104. Schnierle BS, Groner B. Retroviral targeted delivery. Gene Ther. 3(12), 1069-1073 (1996).
105. Howitt J, Anderson CW, Freimuth P. Adenovirus interaction with its cellular receptor CAR. Curr. Top. Microbiol. Immunol. 272, 331-364 (2003).
106. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44(10), 1094-1104 (2011).
107. Arcasoy SM, Latoche JD, Gondor M, Pitt BR, Pilewski JM. Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Gene Ther. 4(1), 32-38 (1997).
108. Michen B, Graule T. Isoelectric points of viruses. J. Appl. Microbiol. 109(2), 388-397 (2010).
109. Wolfer DP, Lang R, Cinelli P, Madani R, Sonderegger P. Multiple roles of neurotrypsin in tissue morphogenesis and nervous system development suggested by the mRNA expression pattern. Mol. Cell. Neurosci. 18(4), 407-433 (2001).
110. Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J. Clin. Invest. 100(5), 1144-1149 (1997).
111. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J. Virol. 65(3), 1202-1207 (1991).
112. Denby L, Work LM, Graham D et al. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 15(11), 1054-1064 (2004).
113. Eto Y, Yoshioka Y, Asavatanabodee R et al. Transduction of adenovirus vectors modified with cell-penetrating peptides. Peptides 30(8), 1548-1552 (2009).
114. Lehmusvaara S, Rautsi O, Hakkarainen T, Wahlfors J. Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells. Biotechniques 40(5), 573-574 (2006).
115. Youn JI, Park SH, Jin HT et al. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. Cancer Gene Ther. 15(11), 703-712 (2008).
116. Kuhnel F, Schulte B, Wirth T et al. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. J. Virol. 78(24), 13743-13754 (2004).
117. Chen HZ, Wu CP, Chao YC, Liu CYY. Membrane penetrating peptides greatly enhance baculovirus transduction efficiency into mammalian cells. Biochem. Biophys. Res. Commun. 405(2), 297-302 (2011).
118. Park SH, Doh J, Park SI et al. Branched oligomerization of cell-permeable peptides markedly enhances the transduction efficiency of adenovirus into mesenchymal stem cells. Gene Ther. 17(8), 1052-1061 (2010).
119. Liu SH, Mao QW, Zhang WF et al. Genetically modified adenoviral, vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells. Biosci. Rep. 29(2), 103-109 (2009).
120. Yoshioka Y, Asavatanabodee R, Eto Y et al. Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci. 83(21-22), 747-755 (2008).
121. Nigatu, AS, Vupputuri S, Flynn N, Neely BJ, Ramsey JD. Evaluation of cell-penetrating peptide/adenovirus particles for transduction of CAR-negative cells. J. Pharm. Sci. 102(6), 1981-1993 (2013).
122. Berlose JP, Convert O, Derossi D, Brunissen A, Chassaing G. Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments. Eur. J. Biochem. 242(2), 372-386 (1996).
123. Rothbard JB, Garlingto S, Lin Q et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6(11), 1253-1257 (2000).
124. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 278(13), 11411-11418 (2003).
125. Kim TI, Ou M, Lee M, Kim SW. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 30(4), 658-664 (2009).
126. Kim P-H, Kim T-I, Yockman JW, Kim SW, Yun C-O. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 31(7), 1865-1874 (2010).
127. Wadhwa MS, Collard WT, Adami RC, McKenzie DL, Rice KG. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconj. Chem. 8(1), 81-88 (1997).
128. McKenzie DL, Collard WT, Rice KG. Comparative gene transfer efficiency of low molecular weight polylysine DNA-condensing peptides. J. Pept. Res. 54(4), 311-318 (2003).
129. Åmand HL, Rydberg HA, Fornander LH, Lincoln P, Nordén B, Esbjörner EK. Cell surface binding and uptake of arginine-and lysine-rich penetratin peptides in absence and presence of proteoglycans. Biochim. Biophys. Acta 1818(11), 2669-2678 (2012).
130. McKenzie DL, Kwok KY, Rice KG. A potent new class of reductively activated peptide gene delivery agents. J. Biol. Chem. 275(14), 9970-9977 (2000).
131. Read ML, Singh S, Ahmed Z et al. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 33(9), e86-e86 (2005).
132. Siomi H, Shida H, Maki M, Hatanaka M. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 64(4), 1803-1807 (1990).
133. Friedler A, Friedler D, Luedtke NW, Tor Y, Loyter A, Gilon C. Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif. J. Biol. Chem. 275(31), 23783-23789 (2000).